Meanwhile, the U.K.'s Medicines and Healthcare Products Regulatory Agency updated its warnings on GLP-1 and dual GLP-1/GIP ...

Add Yahoo as a preferred source to see more of our stories on Google. This article is part of “Innovations In: Type 1 Diabetes,” an editorially independent special report that was produced with ...

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for curbing dementia risk in people with the condition, finds the largest study of ...

We urgently call upon the Food and Drug Administration (FDA) to prioritize the approval of sotagliflozin — a treatment that was approved in Europe five years ago. Sotagliflozin offers the opportunity ...

A major new study reveals that older adults with cancer and type 2 diabetes who take GLP-1 receptor agonist medications (GLP-1RAs) experience significantly better overall survival rates compared to ...

A Garvan Institute of Medical Research-led clinical trial has found that using the type 2 diabetes (T2D) drug metformin reduces insulin needs in type 1 diabetes (T1D), a finding that could potentially ...

This article is part of “Innovations In: Type 1 Diabetes,” an editorially independent special report that was produced with financial support from Vertex. In 2024 Stephen Rich and his colleagues ...

There’s a cliché in the type 1 diabetes community that a cure has been “five years away” for as long as anyone can remember. For decades, patients have been told that researchers were on the verge of ...

A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The study was published in Neurology. Subscribe to ...

A simple finger-prick blood test can find those at risk so they can get the right treatment.